CMS Biosimilar Reimbursement Shift: What You Need to Know Last Updated: November 16, 2017
Filed under:
Print Friendly, PDF & Email

The Center for Biosimilars: Sonia Oskouei: The world of biosimilars is constantly evolving, with many developments occurring in just the past few weeks. On November 2, 2017, CMS announced a significant decision to change the existing policy on biosimilar reimbursement under Medicare Part B. As part of the final CY2018 Medicare Physician Fee Schedule (PFS) policy, biosimilars will each have unique Healthcare Common Procedure Coding System (HCPCS) codes and payments under Medicare Part B, starting January 1, 2018.

Full story